Grove Bank & Trust Sells 5,268 Shares of Illumina, Inc. (NASDAQ:ILMN)

Grove Bank & Trust lessened its position in Illumina, Inc. (NASDAQ:ILMN) by 92.8% in the 4th quarter, Holdings Channel reports. The firm owned 409 shares of the life sciences company’s stock after selling 5,268 shares during the period. Grove Bank & Trust’s holdings in Illumina were worth $57,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. J.P. Morgan Private Wealth Advisors LLC bought a new stake in Illumina in the third quarter valued at approximately $29,558,000. Aquila Investment Management LLC increased its stake in Illumina by 150.0% in the fourth quarter. Aquila Investment Management LLC now owns 25,000 shares of the life sciences company’s stock valued at $3,481,000 after purchasing an additional 15,000 shares in the last quarter. Weil Company Inc. increased its stake in Illumina by 59.2% in the third quarter. Weil Company Inc. now owns 22,963 shares of the life sciences company’s stock valued at $3,152,000 after purchasing an additional 8,539 shares in the last quarter. Vanguard Group Inc. increased its stake in Illumina by 15.0% in the third quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock valued at $2,466,614,000 after purchasing an additional 2,336,935 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd increased its stake in Illumina by 60.6% in the third quarter. Harvest Fund Management Co. Ltd now owns 1,246 shares of the life sciences company’s stock valued at $171,000 after purchasing an additional 470 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Insider Transactions at Illumina

In related news, CEO Jacob Thaysen bought 7,330 shares of the business’s stock in a transaction dated Thursday, February 22nd. The stock was bought at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the purchase, the chief executive officer now owns 14,861 shares in the company, valued at approximately $2,010,544.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.17% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ILMN has been the subject of several research reports. Royal Bank of Canada reissued an “outperform” rating and set a $253.00 price objective on shares of Illumina in a research report on Tuesday, April 9th. StockNews.com raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Scotiabank raised shares of Illumina from a “sector perform” rating to a “sector outperform” rating and set a $185.00 price objective for the company in a research report on Monday, December 18th. Stephens reissued an “overweight” rating and set a $170.00 price objective on shares of Illumina in a research report on Wednesday, April 10th. Finally, Barclays increased their price objective on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research report on Wednesday, April 10th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $167.70.

Illumina Trading Down 4.7 %

Shares of ILMN stock opened at $121.16 on Tuesday. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.26. The company has a fifty day moving average price of $135.35 and a two-hundred day moving average price of $128.35. Illumina, Inc. has a one year low of $89.00 and a one year high of $232.23.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The company had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. Illumina’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.14 EPS. On average, research analysts anticipate that Illumina, Inc. will post 0.91 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.